番茄社区

Balancing aspiration risk with the consequences of medication discontinuation

Addition of GLP-1 drugs led to an even greater reduction

News and commentary from the endocrinology world

Most are eligible for weight management indication

In the third year, 88% of patients could go 12 weeks or longer with 8-mg dose

SUMMIT trial able to show clinical benefit beyond quality-of-life improvement

Also in TTHealthWatch: frailty as a predictor of dementia

Real-world data suggested semaglutide, liraglutide reduced AUD-related hospitalizations

News and commentary from the endocrinology world

Also in TTHealthWatch: early sugar exposure, hypertension, and diabetes

Labels now caution about pulmonary aspiration risk

Ophthalmologists hope expanded use will lead to more evaluations in primary clinics

Health news and commentary gathered by 番茄社区 staff

Nearly all participants in SURMOUNT-1 avoided diabetes with the GLP-1/GIP receptor agonist